US Bancorp
KALV

US Bancorp’s KalVista Pharmaceuticals KALV Stock Holding History

US Bancorp’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.3K Sell
708
-2
-0.3% -$32 ﹤0.01% 3238
2025
Q4 		$11.5K Buy
710
+63
+10% +$834 ﹤0.01% 3288
2025
Q3 		$7.88K Buy
647
+114
+21% +$1.57K ﹤0.01% 3391
2025
Q2 		$6.03K Sell
533
-37
-6% -$452 ﹤0.01% 3582
2025
Q1 		$6.58K Buy
+570
New +$5.82K ﹤0.01% 3573
2022
Q4 		– Sell
-2,984
Closed -$43K – 4217
2022
Q3 		$43K Buy
+2,984
New +$41.7K ﹤0.01% 2630
2021
Q3 		– Sell
-113
Closed -$3K – 4131
2021
Q2 		$3K Buy
+113
New +$2.96K ﹤0.01% 3733

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

US Bancorp's KALV Position: Q1 2026 in Review

US Bancorp reduced its KalVista Pharmaceuticals (KALV) stake by 0.28% in Q1 2026, selling an estimated $32 and leaving 708 shares worth $14.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3238.

US Bancorp first reported a position in KALV in Q2 2021 and has held it in 7 quarters since. The position peaked at $43K in Q3 2022. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • US Bancorp held 708 shares of KalVista Pharmaceuticals worth $14.3K as of Q1 2026.
  • US Bancorp sold 2 KalVista Pharmaceuticals shares in Q1 2026, an estimated $32.
  • KalVista Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #3238 holding.
  • US Bancorp first reported a position in KalVista Pharmaceuticals in Q2 2021 and has held it in 7 quarters since.
  • US Bancorp's KalVista Pharmaceuticals position peaked at $43K in Q3 2022.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.